3M Company Company Profile and SWOT Analysis 3M Company 3M

Document Sample
3M Company Company Profile and SWOT Analysis 3M Company 3M
3M Company



_________________________________________________________________________________







3M Company Financial Snapshot



Operating Performance

Fast Facts

3M Center, St. Paul, 55144,United States of The company reported revenues of US$26,662.00

Headquarters Address

America million during 2010, with a CAGR of 3.85% during

2006–2010. Its revenue grew at an annual rate of

Telephone + 1 651 7331110

15.31% over the previous fiscal year. In 2010, the

company recorded an operating margin of 22.20%, as

Fax + 1 651 7339973 against 20.82% in 2009.



Website www.3m.com

Revenue and Margins

Ticker Symbol, Stock Exchange MMM, New York Stock Exchange



Number of Employees 74,835



Fiscal Year End December



Revenue (in US$ million) 26,662.00









SWOT Analysis



Strengths Weaknesses Return on Equity



Improving Liquidity Position Decline in Revenue The company recorded a return on equity (ROE) of

26.08% for 2010, as compared to its peers, Baxter

Respirator Mask and Asbestos International Inc. (Ticker: BAX), DENTSPLY

Improving Operating Margin International Inc. (Ticker: XRAY) and Nobel Biocare

Litigation

Holding AG (Ticker: NOBN), which recorded ROEs of

Strengthening Solvency Position 21.62%, 14.45% and 14.27% respectively. The

company reported an operating margin of 22.20% in

2010.

Opportunities Threats

Increasing demand for LCD TV and Return on Equity

Environmental Regulations

Laptops



Positive Outlook of Automotive Industry Negative Construction Outlook for US



Remodeling Business In the US Rising Labor Cost









Liquidity Position



The company reported a current ratio of 2.01 in 2010,

as compared to its peers, Baxter International Inc.,

DENTSPLY International Inc. and Nobel Biocare

Holding AG, which recorded current ratios of 1.98,

3.65 and 1.03 respectively. As of December 2010, the

company recorded cash and short-term investments

of worth US$4,478.00 million, against zero current

debt. The company reported a debt to equity ratio of

0.35 in 2010 as compared to its peers, Baxter

International Inc., DENTSPLY International Inc. and

Nobel Biocare Holding AG, which recorded debt to

equity ratios of 0.67, 0.33 and 0.79 respectively.









___________________________________________________________________________________________



3M Company - SWOT Profile Page 1

3M Company



_________________________________________________________________________________





TABLE OF CONTENTS



1 Business Analysis ................................................................................................................................... 5

1.1 Company Overview ................................................................................................................................................5

1.2 Business Description ..............................................................................................................................................5

1.3 Major Products and Services .................................................................................................................................6

2 Analysis of Key Performance Indicators ............................................................................................... 9

2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................9

2.2 Key Financial Performance Indicators .................................................................................................................12

2.2.1 Revenue and Operating Profit .........................................................................................................................12

2.2.2 Asset, Liabilities and Capex .............................................................................................................................13

2.2.3 Net Debt vs. Gearing Ratio ..............................................................................................................................14

2.2.4 Operational Efficiency ......................................................................................................................................15

2.2.5 Solvency ..........................................................................................................................................................16

2.2.6 Valuation ..........................................................................................................................................................17

2.3 Competitive Benchmarking ..................................................................................................................................18

2.3.1 Market Capitalization .......................................................................................................................................18

2.3.2 Efficiency ..........................................................................................................................................................19

2.3.3 Capital Expenditure..........................................................................................................................................20

2.3.4 Valuation ..........................................................................................................................................................21

2.3.5 Turnover – Inventory and Asset .......................................................................................................................22

2.3.6 Liquidity ............................................................................................................................................................23

3 Mergers & Acquisitions and Partnerships ........................................................................................... 24

3.1 M&A and Partnerships Strategy ...........................................................................................................................24

4 Recent Developments ...................................................................................

By registering with docstoc.com you agree to our
privacy policy and terms of service

Successfully added document to cart!

Successfully added document to cart!